Skip to Main Content
Our Commitment to Diversity

340B Drug Pricing Program 2021 Outlook

Share via LinkedIn
Share via Twitter
Share via Facebook
Date: 19 March 2021
Triage
By: Andrew D. Ruskin

In this episode, Richard Church and Andrew Ruskin discuss recent developments in the landscape of the 340B Drug Pricing Program in 2020, and forecast some of the major areas of focus and potential change for 340B covered entities under the new administration in 2021 and beyond.

Andrew D. Ruskin
Andrew D. Ruskin
Washington DC
Find more items tagged as: 340B Program and Pharmacy, Health Care and FDA, Health Care Sector, Policy and Regulatory
Return to top of page

Email Disclaimer

We welcome your email, but please understand that if you are not already a client of K&L Gates LLP, we cannot represent you until we confirm that doing so would not create a conflict of interest and is otherwise consistent with the policies of our firm. Accordingly, please do not include any confidential information until we verify that the firm is in a position to represent you and our engagement is confirmed in a letter. Prior to that time, there is no assurance that information you send us will be maintained as confidential. Thank you for your consideration.

Accept Cancel